Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
HANGZHOU and SHAOXING, China, Jan. 24, 2024 /PRNewswire/ Ascletis Pharma Inc. today announces dosing of the first patient in Phase III clinical trial of ASC40 for treatment of moderate to.
Up to 68.2% mean relative reduction in liver fat content from baseline in biopsy-confirmed non-alcoholic steatohepatitis patients receiving 12-week treatment of ASC41 tablet At Week 12, up to.